|
(b)(4).This is a combination product, and the event is being reviewed for both the suture and the triclosan.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.The patient demographic info: weight, bmi at the time of index procedure date of the index surgical procedure.The diagnosis and indication for the index surgical procedure? in what tissue was the pds plus and monocryl plus sutures placed? what was the tissue condition, i.E., normal or thin, calcified, fragile, diseased? was this a bilateral breast procedure? if yes, were the sutures used in both breasts? if a bilateral procedure, was the reaction noted in both breasts? was medical or surgical intervention provided to the patient? if yes, please describe and provide dates.What were the current symptoms following the index surgical procedure? -onset date? was allergy testing for triclosan performed? if yes, results? does the patient have a known sensitivity to triclosan? was a culture performed of wound discharge? if yes, results? did the patient experience wound dehiscence? other relevant patient history/concomitant medications.Lot number.What is the physician¿s opinion as to the etiology of or contributing factors to this event? what is the patient¿s current status? the device is not being returned.If the device or further details are received at a later date a supplemental medwatch will be sent.Trade name - irgacare®.Active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿= 2360 ug/m.Note: events reported via mw # 2210968-2021-01706.
|
|
Date sent to the fda: 04/22/2021.H6 component code: g07002 ¿ device not returned.To date the device has not been returned.If the device or further details are received at the later date a supplemental medwatch will be sent.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|